Free brain tumor drug in Uruguay: how long patients lived
Original title: Real-World Survival Outcomes of Glioblastoma Patients Under Universal Temozolomide Access in Uruguay: A Retrospective Cohort Study (2009-2018) and Implications for Health Policy.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This drug is already standard care that a doctor can give today.
The short version
Uruguay pays for a standard brain tumor drug for everyone, and this study looked at how long those patients lived.
What was studied. Doctors looked back at the records of 32 adults with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary at one hospital in Montevideo, Uruguay. All were diagnosed and treated between 2009 and 2017, after the country began paying for the drug temozolomide.
What they found. Half of the 32 patients lived longer than 17 months, and half lived less. For people who finished the full drug and radiation plan, the typical time lived was 24 months. For people who did not finish it, the typical time was 11 months. Men made up 62.5% of the group, and the whole visible tumor was removed in 56.3% of cases.
What this means, and what it doesn't
What it could mean: It suggests that paying for this standard drug let patients in Uruguay do about as well as patients in richer countries. It also suggests that finishing the full treatment plan matters.
What it doesn't mean: This is not a new treatment, and it is not a cure. The doctors only read old records from 32 people at one hospital. A look-back study like this cannot prove what caused the results. It does not tell any one person how long they will live, and it does not change what your own doctor offers you.
Source: PubMed, July 24, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.